A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-Site, Open-Label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.
The study terminated on 08MAR2016 as it met its objectives of characterizing long term safety and tolerability. The study did not terminate due to safety concerns.
Inclusion Criteria:
Exclusion Criteria:
Ormond Beach, Florida 32174, United States
Boston, Massachusetts 02114, United States
Clinton, Michigan 48038, United States
Fort Gratiot, Michigan 48059, United States
Lebanon, New Hampshire 03756, United States
New York, New York 10016, United States
New York, New York 10016, United States
Chapel Hill, North Carolina 27514, United States
Pittsburgh, Pennsylvania 15213, United States
Caba, C1114AAP, Argentina
CABA, C1125ABD, Argentina
São Paulo, São Paulo 05403-900, Brazil
São Paulo, 05403-000, Brazil
Bogota, Cundinamarca 0000, Colombia
Bogota, Cundinamarca, Colombia
Bogotá, Cundinamarca 110221, Colombia
Zagreb, 10000, Croatia
Plzen-Bory, 30599, Czechia
Copenhagen NV, 2400, Denmark
Tübingen, Baden-Wurttemberg 72076, Germany
Ioannina, 45500, Greece
Thessaloniki, 56403, Greece
Kecskemét, 6000, Hungary
Nyíregyháza, 4400, Hungary
Nyíregyháza, 4400, Hungary
Szeged, 6720, Hungary
Shinjuku-ku, Tokyo 169-0073, Japan
Gdansk, 80-402, Poland
Szczecin, 70-111, Poland
Wroclaw, 50-368, Poland
Banská Bystrica, 975 17, Slovakia
Simferopol, Autonomous Republic of Crimea 95006, Ukraine
Kyiv, 01601, Ukraine